Chronic Kidney Disease Market By Treatment Type (Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Diuretics; Calcium Channel Blockers; Others); By End-User (Hospitals; Specialty Clinics; Dialysis Centers; Research & Academic Institutes); By Diagnosis Method (Blood Tests; Urine Tests; Imaging Tests (Ultrasound, CT Scan, MRI); Kidney Biopsy); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Chronic Kidney Disease Market Size & Overview

The chronic kidney disease (CKD) market was valued at $85.4 billion in 2024 and is projected to reach $120.7 billion by 2030, expanding at a CAGR of 5.9% during the forecast period.

 

Chronic kidney disease is a progressive condition characterized by the gradual loss of kidney function over time, leading to severe complications such as end-stage renal disease (ESRD), cardiovascular disorders & metabolic imbalances. The growing prevalence of diabetes, hypertension, obesity, and aging populations is a key driver of CKD cases worldwide. The market encompasses diagnostics, pharmaceuticals, dialysis treatments, and kidney transplantation services, with an increasing focus on early-stage disease management, personalized medicine & innovative therapies.

 

The demand for novel therapeutics, including SGLT2 inhibitors (like dapagliflozin and canagliflozin), endothelin receptor antagonists, and anti-inflammatory agents, is rising as healthcare providers shift toward slowing disease progression and reducing CKD-related complications. Additionally, advancements in biomarkers, artificial kidneys & regenerative medicine are shaping the future of CKD treatment. However, high treatment costs, limited awareness in developing regions, and access barriers to advanced therapies remain challenges for market expansion.

 

Chronic Kidney Disease Market Dynamics:

Market Drivers

Rising Global Prevalence of Chronic Kidney Disease (CKD) and Related Risk Factors

The increasing incidence of diabetes, hypertension, and obesity—major risk factors for CKD—is significantly driving market growth. According to the Centers for Disease Control & Prevention (CDC), 15% of U.S. adults (37 million people) suffer from CKD, with many cases undiagnosed. Similarly, the International Diabetes Federation (IDF) reported that over 537 million adults worldwide had diabetes in 2021, a key contributor to kidney disease. As these chronic conditions continue to rise, so does the demand for early diagnosis, dialysis treatments, and renal replacement therapies, propelling the CKD market forward.

Technological Advancements in Diagnostic Tools & Treatment Modalities

The CKD market is benefiting from significant innovations in diagnostics, dialysis machines & kidney transplantation techniques. Bioartificial kidneys such as those under development by the Kidney Project (University of California, San Francisco) aim to provide a breakthrough alternative to dialysis and transplants. Additionally, AI-powered diagnostic tools are improving the early detection of CKD through predictive analytics & biomarkers, enhancing patient outcomes. Such advancements contribute to increased investment in CKD research & treatment solutions, fueling market expansion.

 

Market Opportunities:

Growing Adoption of Home-Based Dialysis & Telemedicine Solutions

With the global healthcare sector shifting towards patient-centered and remote care, home-based dialysis solutions present a major growth opportunity. According to the National Kidney Foundation (NKF), home hemodialysis (HHD) and peritoneal dialysis (PD) have seen a 15-20% increase in adoption over the past five years. Companies like Fresenius Medical Care & Baxter International are expanding their home dialysis product portfolios, enabling patients to manage CKD conveniently. Additionally, telemedicine platforms allow nephrologists to monitor patients remotely, further enhancing accessibility to CKD management.

Emerging Markets & Government Initiatives for CKD Management

Developing countries in Asia-Pacific, Latin America, and Africa present untapped potential due to the rising CKD burden and increasing healthcare investments. According to the World Health Organization (WHO), low- and middle-income countries will account for 70% of CKD cases by 2040. Governments in countries like India & China are implementing national kidney health programs and public health insurance schemes to improve access to dialysis and transplantation. For instance, India’s Pradhan Mantri National Dialysis Program (PMNDP) provides free dialysis services to low-income patients, increasing the demand for CKD-related treatments.

 

Market Restraints:

High Treatment Costs and Limited Accessibility to Advanced Therapies

CKD treatment, especially dialysis and kidney transplantation, remains expensive and out of reach for many patients, particularly in developing economies. In the U.S., the annual cost of dialysis per patient exceeds $90,000, while kidney transplants can cost up to $400,000, including pre- and post-surgical care. Additionally, out-of-pocket expenses for medications such as erythropoiesis-stimulating agents (ESAs) and phosphate binders pose a significant financial burden on patients. Many low-income individuals in Asia, Africa, and Latin America lack adequate insurance coverage, restricting access to life-saving CKD treatments.

Shortage of Donor Kidneys and Dependence on Dialysis

While kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), a global shortage of donor kidneys remains a major challenge. The United Network for Organ Sharing (UNOS) reports that nearly 90,000 people in the U.S. are currently on the kidney transplant waiting list, with an average waiting time of 3 to 5 years. This scarcity forces most CKD patients to rely on dialysis as a long-term treatment, which not only reduces quality of life but also leads to higher healthcare costs and increased mortality rates. Innovative alternatives such as bioengineered kidneys and xenotransplantation (using animal organs) are being explored, but widespread adoption is still years away.

 

Chronic Kidney Disease Market Segmentation: A Comprehensive Overview

By Treatment Type

• Angiotensin-Converting Enzyme (ACE) Inhibitors

• Angiotensin II Receptor Blockers (ARBs)

• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Diuretics

• Calcium Channel Blockers

• Others

 

By End-User

• Hospitals

• Specialty Clinics

• Dialysis Centers

• Research & Academic Institutes

By Diagnosis Method

• Blood Tests

• Urine Tests

• Imaging Tests (Ultrasound, CT Scan, MRI)

• Kidney Biopsy

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Chronic Kidney Disease Market Segment Analysis: Growth Trends Across Categories

By Treatment Type:

Leading Segment: Angiotensin-Converting Enzyme (ACE) Inhibitors

ACE inhibitors dominate the chronic kidney disease (CKD) treatment market, capturing the largest market share. These medications are widely prescribed for CKD patients as they help control blood pressure, reduce proteinuria & slow the progression of kidney damage. According to recent reports, ACE inhibitors account for nearly 30% of the global CKD treatment market. Their ability to improve renal function and prevent further kidney damage makes them a cornerstone in the treatment of CKD, especially in early stages.

Fastest-Growing Segment: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

SGLT2 inhibitors are the fastest-growing treatment segment for CKD, with a CAGR of 8-10%. The rise in their use can be attributed to their dual benefit of controlling blood glucose & reducing kidney damage, making them increasingly popular for CKD patients with diabetes. The recent approval of drugs like Empagliflozin & Dapagliflozin has led to a significant increase in their adoption, especially in advanced stages of CKD, where the risk of cardiovascular complications is high.

 

By End-User:

Leading Segment: Hospitals

Hospitals represent the largest share of the CKD treatment market, accounting for approximately 40% of the total market. Hospitals play a central role in diagnosing & treating CKD, providing access to nephrologists, specialized diagnostic tools & advanced treatment facilities such as dialysis. The growing prevalence of CKD, particularly in aging populations, ensures that hospitals continue to dominate the market.

Fastest-Growing Segment: Dialysis Centers

Dialysis centers are the fastest-growing end-user segment, with a CAGR of 6-8%. As CKD progresses to end-stage renal disease (ESRD), the demand for dialysis increases, driving the growth of dialysis centers globally. In regions like North America & Europe, specialized dialysis centers are expanding to accommodate the growing number of CKD patients who require regular dialysis treatments.

 

By Diagnosis Method:

Leading Segment: Blood Tests

Blood tests lead the CKD diagnosis market, holding the largest market share at 35-40%. These tests are used to assess kidney function by measuring serum creatinine, glomerular filtration rate (GFR), and other relevant biomarkers. Blood tests are commonly the first step in diagnosing CKD and are widely used in both primary care and specialized nephrology settings.

Fastest-Growing Segment: Imaging Tests (Ultrasound, CT Scan, MRI)

Imaging tests are experiencing rapid growth with a CAGR of 7-9%. As the technology behind imaging improves, non-invasive methods for detecting structural changes in the kidneys have become more popular. Ultrasound and MRI imaging are now commonly used to monitor the progression of kidney damage, helping doctors identify cysts, tumors, and obstructions in the kidneys that can contribute to CKD.

 

By Region:

Leading Region: North America

North America holds the largest market share in the chronic kidney disease market, accounting for around 35-40% of the global market. The U.S. has the highest prevalence of CKD due to factors like diabetes, hypertension & an aging population. Additionally, North America benefits from a robust healthcare infrastructure, access to advanced treatments, & the presence of leading pharmaceutical companies.

Fastest-Growing Region: Asia-Pacific

The APAC region is the fastest-growing market for CKD treatments, with a projected CAGR of 7-9%. Countries like China & India are experiencing a rise in CKD due to lifestyle changes, urbanization, and increasing healthcare awareness. Additionally, the expansion of healthcare infrastructure & government initiatives to tackle chronic diseases are driving the demand for CKD treatments in the region.

 

Chronic Kidney Disease (CKD) Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 85.4 Billion
Revenue Forecast in 2030	USD 120.7 Billion
Overall Growth Rate	CAGR of 5.9% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Treatment Type, By End-User, By Diagnosis Method, By Geography
By Treatment Type	Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Diuretics; Calcium Channel Blockers; Others
By End-User	Hospitals; Specialty Clinics; Dialysis Centers; Research & Academic Institutes
By Diagnosis Method	Blood Tests; Urine Tests; Imaging Tests (Ultrasound, CT Scan, MRI); Kidney Biopsy
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of CKD, increasing adoption of SGLT2 inhibitors, growing demand for advanced diagnostic methods
Pricing and Purchase Options	Customized options available

 

Key Players in the Chronic Kidney Disease Market

• AstraZeneca

• Amgen Inc.

• Hoffmann-La Roche Ltd.

• GlaxoSmithKline plc

• AbbVie Inc.

• Pfizer Inc.

• Sanofi

• Bayer AG

• Boehringer Ingelheim

• Novartis AG

 

Recent Developments

• In April 2024, AstraZeneca unveiled the IMPACT CKD model at the ISN World Congress of Nephrology. This comprehensive analysis forecasts that up to 16.5% of the population across eight countries will be affected by CKD by 2032, with advanced-stage cases potentially increasing by 59.3%. The study emphasizes the urgent need for early diagnosis & intervention to mitigate the profound economic & environmental impacts of CKD progression.

• In August 2024, the U.S. Food and Drug Administration approved Novartis' drug Fabhalta for reducing excess protein in the urine of patients with IgA nephropathy (IgAN), a kidney disease that primarily affects young adults. This approval positions Fabhalta as a competitive treatment in the IgAN market, alongside existing therapies like Calliditas' Tarpeyo and Travere Therapeutics' Filspari.

• In September 2024, Amgen announced plans to test its obesity drug candidate, MariTide, in patients at risk of weight-related conditions, including kidney diseases. This initiative aims to address the interconnectedness of obesity & CKD by evaluating MariTide's efficacy in reducing the progression of kidney-related ailments. Amgen's approach reflects a broader industry trend of repurposing weight-loss medications to manage comorbid conditions associated with obesity.

 

Future Outlook

The future outlook for the chronic kidney disease (CKD) market is highly optimistic, driven by rising disease prevalence, advancements in targeted therapies & increasing global awareness about early diagnosis and management. The growing incidence of diabetes & hypertension, which are major risk factors for CKD, will continue to fuel demand for effective treatments. Innovative therapeutics, such as SGLT2 inhibitors, endothelin receptor antagonists & novel anti-inflammatory drugs, are expected to transform the treatment landscape by slowing disease progression and improving patient outcomes. Additionally, advancements in biomarker research & AI-powered diagnostics are likely to enhance early detection and personalized treatment approaches. However, high treatment costs, limited access to advanced therapies in low-income regions, and challenges in organ transplantation and dialysis affordability may pose restraints. Despite these challenges, expanding healthcare infrastructure in emerging markets, government initiatives promoting CKD awareness, and continued R&D investments in nephrology are expected to drive sustained growth in the CKD market over the next decade.